Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination

Joshua W Fleming  
Laurie W Fleming  
Courtney S Davis  
Department of Pharmacy Practice,  
The University of Mississippi School of Pharmacy, Jackson, MS, USA

Abstract: Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodium–glucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the safety and efficacy of canagliflozin and metformin from data obtained from Phase III metformin add-on therapy clinical trials as there are no studies to date that specifically evaluate the combination of metformin and canagliflozin. Trials included in this review were dual-therapy trials of subjects who were already taking background metformin and were assigned to receive canagliflozin, glimepiride, or sitagliptin. The addition of canagliflozin to metformin resulted in a decrease in HbA1c of 0.73%–0.93%. Canagliflozin 100 mg was considered to be non-inferior to glimepiride and sitagliptin 100 mg with the canagliflozin 300 mg dose being statistically superior to sitagliptin and glimepiride. Other advantages of the use of canagliflozin are reduction in weight (3.3–4.0 kg) and systolic blood pressure (3.3–4.7 mmHg). The primary disadvantages are potential genital mycotic infections, hypotension, and gastrointestinal side effects from metformin. All things considered, this combination appears to be safe and effective in clinical trials and represents a promising option for the treatment of T2DM.

Keywords: type 2 diabetes, fixed-dose combination (FDC), canagliflozin metformin

Introduction to the developments and management issues in type 2 diabetes

The increasing prevalence of diabetes is a global health concern. Worldwide, it is estimated that 347 million people have diabetes. Type 2 diabetes mellitus (T2DM) accounts for 90%–95% of cases of diabetes diagnosed in adults and is associated with increased risk of stroke, heart disease, kidney failure, blindness, non-traumatic lower-limb amputations, and premature death. In the US alone, approximately 29.1 million people (9.3% of the population) have diabetes with total medical costs estimated to be $245 billion in 2012. Health care expenditures for patients with diabetes are estimated to be 2.3 times higher compared to those without diabetes.

Glycemic control is necessary to slow the progression of microvascular and macrovascular complications. The multifaceted pathology of the disease complicates its management. The pathogenesis of diabetes includes β-cell dysfunction, impaired tissue glucose utilization, and increased hepatic glucose and free fatty acid production. Genetic predisposition may increase the likelihood of developing T2DM, but environmental factors, including obesity, sedentary lifestyles, and age, increase the risk of developing insulin resistance.
Due to the complexity of the disease, many patients with T2DM require multiple oral anti-hyperglycemic agents (AHAs) and even insulin therapy to maintain adequate blood glucose control. In addition, patients often require treatment for both dyslipidemia and hypertension. A US survey of 875 adults with diabetes aged ≥50 years found that 50% of respondents were using greater than or equal to seven medications, including greater than or equal to two AHAs. Most studies report a 65%–85% adherence rate to oral AHA, although rates can be lower (36%–54%) for regimens requiring more frequent dosing. A large, longitudinal study of medical claims data from a US managed-care company over a 3-year period found that improved adherence to diabetes medications was associated with 13% less risk of subsequent hospitalizations or emergency department visits and decreased medical costs.

History, development, and rationale for increasing use of fixed-dose combinations in diabetes

Combination products can simplify treatment regimens for patients, which is especially important for patients with diabetes on multiple medications. A meta-analysis of nine studies consisting of patients with chronic disease states, inclusive of diabetes and hypertension, was conducted to compare medication compliance with fixed-dose combination (FDC) vs free-drug component regimens. A 26% relative risk (RR) reduction in noncompliance was seen in the FDC group (RR 0.74; 95% confidence interval, 0.69–0.80). Another analysis with T2DM patients taking either FDC or a combination of single pills showed increased compliance, improved satisfaction, and lower direct medical costs in patients receiving the FDC.

The first FDC for the treatment of diabetes, Glucovance®, (glyburide, metformin), combining a sulfonylurea and a biguanide, was approved by the US Food and Drug Administration (FDA) in the early 2000s, and novel combinations have since evolved. FDC products currently approved for the treatment of T2DM with complementary therapeutic approaches to lowering blood glucose include sulfonylurea/metformin, secretagouge/metformin, thiazolidinedione/metformin, thiazolidinedione/sulfonylurea, dipeptidyl peptidase-4 (DPP-4) inhibitor/metformin, and most recently, sodium–glucose co-transporter 2 (SGLT-2) inhibitor/metformin combinations. In August 2014, the FDA approved Invokamet®, an FDC of canagliflozin and metformin, which is the focus of this review.

Pharmacology

This FDC combines the actions of canagliflozin and metformin. Canagliflozin exhibits its effects on glucose control through altering reabsorption of glucose in the kidney. The primary action of the kidney is to reabsorb all glucose back into circulation up to a threshold of approximately 180 mg/dL. Beyond that threshold, the kidneys excrete glucose into the urine. The sodium–glucose co-transporter 1 (SGLT-1) and SGLT-2 are proteins located in the proximal renal tubule. These proteins are responsible for the reabsorption of glucose. SGLT-1 accounts for approximately 10% of the reabsorbed glucose, and SGLT-2 accounts for the remaining 90%. Canagliflozin inhibits SGLT-2 which leads to a decrease in the reabsorption threshold to approximately 60 mg/dL and an increase in the urinary glucose excretion. A dose-dependent reduction in plasma glucose occurs within the first day of dosing. Metformin is known to decrease hepatic glucose production and improve insulin sensitivity by increasing glucose uptake in the peripheral tissues.

Bioequivalence

Six studies were performed to compare the bioequivalence of immediate-release FDC tablets containing canagliflozin and metformin with the concomitant administration of the single components of canagliflozin and metformin in healthy-fed adults. Across all dose levels, when dosed either as FDC or individual components, the pharmacokinetics of canagliflozin and metformin was found to be bioequivalent and well tolerated.

Absorption

Canagliflozin dosing results in a mean absolute oral bioavailability of approximately 65%. When metformin is given under fasting conditions, its absolute bioavailability is 50%–60%.

Distribution

The mean steady-state volume of distribution for canagliflozin is 119 L, which indicates extensive tissue distribution. Canagliflozin is 99% bound to plasma proteins, primarily albumin. Steady-state concentrations are reached after 4–5 days of once-daily dosing. For metformin, after a single dose of metformin 850 mg, the volume of distribution averages 654±358 L. It is negligibly bound to plasma proteins. Steady-state concentrations are reached within 24–48 hours of usual clinical doses.
Metabolism
Canagliflozin is metabolized predominantly by O-glucuronidation. Metformin is excreted unchanged in the urine.13

Excretion
Canagliflozin is excreted primarily via the fecal and renal routes. The terminal half-life is 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively. Metformin is primarily eliminated via the renal route through tubular secretion, with a plasma elimination half-life of 6.2 hours.13

Efficacy
Monotherapy
Canagliflozin as a single agent has had limited trial data, and this is largely represented by one 26-week, randomized, placebo-controlled trial. In this trial, subjects were not allowed to take any other AHA, and the primary endpoint was change in HbA1c from baseline to week 26. Other outcomes that were assessed were proportion of subjects achieving an HbA1c of <7%, changes from baseline in fasting plasma glucose (FPG) and systolic blood pressure (SBP), and percent change from baseline in body weight high-density lipoprotein (HDL) and triglycerides. There were 584 subjects included in the trial with a mean age of 55.4 years and a relatively equal distribution of males and females. Approximately 68% of the subjects enrolled were white followed by 14.7% Asian, 7% black or African American, and 8.6% American Indian, Alaska Native, or other. Subjects in the main study had been diagnosed with diabetes for 4.6 years and had a mean HbA1c of 8% with a body mass index (BMI) of 31.6 kg/m², and approximately half of those subjects had been on other AHA prior to enrollment. This trial also included a sub-study of subjects with an HbA1c over 10%. This high-glycemic sub-study included 91 subjects with relatively similar characteristics to the subjects enrolled in the main study. In the high-glycemic group, the mean age was slightly younger at 49.3 years, the mean HbA1c was 10.6%, the mean BMI was 30.5 kg/m², duration of diabetes was 4.9 years, and only 23.1% had been on previous AHA prior to enrollment.17

Subjects enrolled in the main study achieved a 0.77% and 1.03% reduction in HbA1c at week 26 in the canagliflozin 100 mg and canagliflozin 300 mg groups, respectively. These results represented a significant reduction in HbA1c over the placebo group which resulted in a 0.14% increase in HbA1c. A significantly greater proportion of subjects on canagliflozin 100 mg (44.5%) and canagliflozin 300 mg (62.4%) achieved a HbA1c of <7% when compared to placebo (20.6%). FPG levels were significantly reduced in the canagliflozin 100 mg (−1.5 mmol/L) and canagliflozin 300 mg (−1.9 mmol/L) over that in the placebo group (0.5 mmol/L). An even greater reduction in postprandial glucose (PPG) was seen in both the canagliflozin 100 mg (−2.4 mmol/L) and canagliflozin 300 mg (−3.3 mmol/L). The high-glycemic sub-study achieved a 2.8% and 3.9% reduction in HbA1c in canagliflozin 100 mg and canagliflozin 300 mg groups, respectively, and an approximate 5 mmol/L reduction in FPG and 7 mmol/L reduction in PPG.17

Canagliflozin-treated subjects also achieved a modest but statistically significant decrease in weight over the course of 26 weeks with a mean loss of 3.4 kg in the high-dose canagliflozin group. In addition to a modest weight loss, subjects receiving 100 mg and 300 mg of canagliflozin achieved a 3.7 mmHg and 5.4 mmHg reduction in SBP, respectively. Finally, treatment with canagliflozin was associated with an approximate 6% increase in HDL over the 26-week trial. The high-glycemic subgroup achieved similar results for weight loss, decrease in SBP, and increase in HDL.17

Metformin use as a single agent has been well studied, and the clinical benefits are known by mostly all clinicians. In a historical trial of metformin monotherapy, subjects with non-insulin-dependent diabetes were enrolled to evaluate the efficacy of metformin. At baseline, these subjects were similar to the subjects enrolled in the canagliflozin monotherapy trial, except that the duration of diabetes was slightly longer at 6 years. The baseline HbA1c was very similar at 8.2%. After 29 weeks, subjects achieved a statistically significant reduction in HbA1c by 1.4%, and a reduction in FPG by 2.9 mmol/L. Subjects also saw a modest weight loss of 0.6 kg, but this was not statistically significant when compared to placebo.18

Comparative data
To date, there are no clinical trials that involve direct comparisons of subjects taking the combination canagliflozin–metformin. In this review, we focus on trials directly comparing canagliflozin to other therapies in subjects who are on background metformin. Comparisons available include glimepiride and sitagliptin, each of which represents an equally viable addition to metformin therapy.19–21

One of the most traditional secondary therapies in type 2 diabetes is the sulfonylurea class. In CANTATA-SU, the addition of canagliflozin was compared to the addition of glimepiride to background metformin in a Phase III, double-blind, randomized, active control, non-inferiority trial. In this
52-week trial, subjects were randomized in a 1:1:1 fashion to receive canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride which was titrated to a maximum dose of 6 mg or 8 mg (mean maximum dose was 5.6 mg) based on the maximum approved dose in the study location. All subjects enrolled were required to be on a stable metformin dose of at least 1,500 mg or greater with an HbA1c of 7%–9.5%. Subjects were not eligible if they had an estimated glomerular filtration rate (eGFR) of less than 55 mL/min/1.73 m² (or less than 60 mL/min/1.73 m² based on the restrictions for metformin at the study center). Additionally, they were required to have a serum creatinine of less than 124 µmol/L for men and less than 115 µmol/L for women. Lastly, subjects with a history of more than one episode of severe hypoglycemia within 6 months prior to enrollment were not allowed to enter the trial.¹⁹

The primary endpoint of this trial was the change in HbA1c from baseline to week 52. Secondary efficacy endpoints included the following: percent change from baseline in body weight; proportion of patients achieving goal HbA1c; change in FPG, SBP, and diastolic blood pressure; and percent change in lipid parameters. The primary analysis was based on a modified intent-to-treat population which included all subjects who received at least one dose of study drug with the last observation carried forward. The trial was designed to prove that the addition of canagliflozin to metformin was non-inferior to the addition of a sulfonylurea. The pre-specified non-inferiority margin was set at 0.3%. If non-inferiority was proven that the addition of canagliflozin to metformin was non-inferior to the addition of a sulfonylurea. The pre-specified non-inferiority margin was set at 0.3%. If non-inferiority was shown, superiority was determined if there was a less than 0% difference when compared to glimepiride.¹⁹

There were 1,450 subjects enrolled in the trial with equal distribution of subjects across the three groups. The mean age at the time of enrollment was 56 years, and the subjects were predominately white (67%) followed by Asian (19%), other (9%), and black or African American (5%). At baseline, subjects had been diagnosed with diabetes for approximately 6.6 years and had a mean HbA1c of 7.8% with a mean FPG of 9.2 mmol/L. The average body weight of subjects enrolled was 86.5 kg with a BMI of 31 kg/m².¹⁹

In the efficacy analysis, both doses of canagliflozin were proven to be non-inferior to glimepiride, and the canagliflozin 300 mg dose reached the pre-specified superiority margin (Table 1). There was no significant difference in the percentage of patients achieving glycemic goal with approximately 60% achieving a goal HbA1c of <7% and 30% achieving a goal of <6.5% across all three groups. Maximum HbA1c benefits were seen with all three groups by week 26. These results were maintained in both of the canagliflozin groups through week 52, but the HbA1c had an upward trend from week 26 to week 52 in the glimepiride group. There was a numerically greater (approaching statistically significant) reduction in FPG in both of the canagliflozin groups as compared to glimepiride.¹⁹

Significant reductions in weight were seen in both of the canagliflozin arms with subjects in the 100 mg group seeing a 4.2% reduction in body weight and patients in the 300 mg group seeing a 4.7% reduction, while the glimepiride group saw a 1% increase in body weight. Subjects receiving canagliflozin 100 mg and 300 mg saw a modest but clinically

### Table 1 Comparison of efficacy endpoints

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Subjects (n)</th>
<th>Duration (weeks)</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cana Mono⁷</td>
<td>RC, DB, PC</td>
<td>584</td>
<td>26</td>
<td>HbA1c (%)</td>
<td>-0.77&lt;sup&gt;a&lt;/sup&gt; -1.03&lt;sup&gt;b&lt;/sup&gt; 0.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FPG (mmol/L)</td>
<td>-1.5&lt;sup&gt;a&lt;/sup&gt; -1.9&lt;sup&gt;b&lt;/sup&gt; 0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weight (kg)</td>
<td>-2.5&lt;sup&gt;a&lt;/sup&gt; -3.4&lt;sup&gt;b&lt;/sup&gt; -0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SBP (mmHg)</td>
<td>-3.7&lt;sup&gt;a&lt;/sup&gt; -5.4&lt;sup&gt;b&lt;/sup&gt; 0.4</td>
</tr>
<tr>
<td>Cana vs SU⁴</td>
<td>RC, DB, AC, NI</td>
<td>1,450</td>
<td>52</td>
<td>HbA1c (%)</td>
<td>-0.82&lt;sup&gt;a&lt;/sup&gt; -0.93&lt;sup&gt;b&lt;/sup&gt; 0.81</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FPG (mmol/L)</td>
<td>-1.35&lt;sup&gt;a&lt;/sup&gt; -1.52&lt;sup&gt;b&lt;/sup&gt; -1.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weight (kg)</td>
<td>-3.7&lt;sup&gt;a&lt;/sup&gt; -4.0&lt;sup&gt;b&lt;/sup&gt; 0.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SBP (mmHg)</td>
<td>-3.3&lt;sup&gt;a&lt;/sup&gt; -4.8&lt;sup&gt;b&lt;/sup&gt; 0.2</td>
</tr>
<tr>
<td>Cana vs Sita¹⁹</td>
<td>RC, DB, AC, PG, NI</td>
<td>1,284</td>
<td>52</td>
<td>HbA1c (%)</td>
<td>-0.73&lt;sup&gt;a&lt;/sup&gt; -0.88&lt;sup&gt;b&lt;/sup&gt; 0.73</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>FPG (mmol/L)</td>
<td>-1.5&lt;sup&gt;a&lt;/sup&gt; -2.0&lt;sup&gt;b&lt;/sup&gt; 1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Weight (kg)</td>
<td>-3.3&lt;sup&gt;a&lt;/sup&gt; -3.7&lt;sup&gt;b&lt;/sup&gt; -1.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SBP (mmHg)</td>
<td>-3.5&lt;sup&gt;a&lt;/sup&gt; -4.7&lt;sup&gt;b&lt;/sup&gt; -0.7</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>P<0.05 when compared to placebo; <sup>b</sup>met pre-specified superiority margins; <sup>c</sup>P<0.05 when compared to glimepiride; <sup>d</sup>P<0.05 when compared to sitagliptin.

Abbreviations: Cana, canagliflozin; Mono, monotherapy; RC, randomized controlled; DB, double-blind; PC, placebo controlled; FPG, fasting plasma glucose; SBP, systolic blood pressure; SU, sulfonylurea; AC, active control; NI, non-inferiority trial; Sita, sitagliptin; PG, parallel crossover group.
significant reduction in SBP. Finally, there were no clinically significant differences in low-density lipoproteins (LDLs), HDLs, or triglycerides.19

The second currently available trial is designed to evaluate the efficacy of canagliflozin as compared to placebo and sitagliptin in patients on metformin monotherapy. This 52-week trial included 1,284 subjects and randomized patients to canagliflozin 100 mg, canagliflozin 300 mg, sitagliptin 100 mg, or placebo in a 2:2:2:1 fashion. The trial was conducted in two periods. The first period lasted 26 weeks and included all four treatment arms. At the end of period one, all patients who were receiving a placebo were transitioned to sitagliptin 100 mg for another 26 weeks. This allowed for a randomized, double-blind, placebo and active control period and a double-blind active control period. All subjects who were randomized to canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg in period one continued with their current treatment during period two. Similar to the sulfonylurea trial, subjects were required to be on a stable dose of metformin of at least 1,500 mg or more with an HbA1c greater than 7%. FPG of subjects could not be >15 mmol/L or <6.1 mmol/L at the end of the run-in period. Notable exclusion criteria included history of cardiovascular disease, uncontrolled hypertension, eGFR of less than 55 mL/min/1.73 m² (or <60 mL/min/1.73 m² based on study center metformin labeling), or serum creatinine greater than 124 µmol/L for men and greater than 115 µmol/L for women.20

The primary endpoint of this trial was the change in HbA1c from baseline to week 26 (period one). The change in HbA1c from baseline to week 56 was a key secondary outcome. Other outcomes that were measured at week 26 were the following: proportion of patients reaching goal HbA1c; change in FPG, PPG, and SBP; and percent change in body weight, triglycerides, and HDL. Outcome measures at week 52 included the following: change in FPG and SBP; and percent change in body weight, triglycerides, and HDL. Primary efficacy analyses were conducted on a modified intent-to-treat population which included all subjects who received at least one dose of the study drug using a last-observation-carried-forward approach. The authors’ prespecified non-inferiority margin for HbA1c was set at 0.3% for the upper limit of the two-sided confidence interval as compared to sitagliptin. The pre-specified superiority margin for HbA1c was set at less than 0% based on the upper bound of the confidence interval.20

Subjects included in this trial had a mean age of 55 years at baseline and had a diagnosis of type 2 diabetes for approximately 7 years with a mean HbA1c of 8%. The approximate mean FPG was 9.2 mmol/L. There was an equal distribution of males and females with the predominate race being white (70%) followed by Asian (15%), other (13%), and black or African American (4%). The mean BMI was 32 kg/m² with an average body weight of 87 kg.20

Glycemic outcomes at week 26 included a statistically significant reduction over placebo in HbA1c for the canagliflozin 100 mg (–0.62%) and canagliflozin 300 mg (–0.77%). No statistical analysis was performed for the sitagliptin group, but the HbA1c lowering was comparable at –0.66%. By week 26, the canagliflozin 100 mg (44.5%) and 300 mg (57.8%) groups had a significantly greater number of subjects achieving an HbA1c of less than 7% when compared to placebo. Of the sitagliptin group, 54.5% achieved an HbA1c of less than 7%. At week 52, both doses of canagliflozin had achieved non-inferiority to sitagliptin 100 mg, and canagliflozin 300 mg had achieved statistical superiority to sitagliptin 100 mg (Table 1). Slightly over half of the subjects randomized to canagliflozin 300 mg and sitagliptin 100 mg achieved an HbA1c of less than 7% compared to approximately 40% in the canagliflozin 100 mg group. Only about one-quarter of all subjects in all three groups achieved an HbA1c of less than 6.5%. Both canagliflozin groups had statistically greater reductions in FPG as compared to sitagliptin with the greatest reduction seen at week 26 (Table 1).20

In terms of the metabolic parameters, we focus on the week 52 endpoints. Both doses of canagliflozin were associated with a statistically significant body weight reduction over sitagliptin with the majority of weight loss seen by week 34 (Table 1). Statistically and clinically significant reductions in SBP were seen in both canagliflozin groups when compared to sitagliptin (Table 1). As with the sulfonylurea trial, there were no statistically significant differences in triglycerides, HDL, or LDL.20

A Phase II trial evaluated twice-daily treatment with canagliflozin, either 50 mg or 150 mg twice daily as an add-on therapy to metformin. This trial closely mimicked how the commercial combination product is dosed. There were 279 patients randomized to 50 mg, 150 mg, or placebo twice daily for 18 weeks after a run-in period with metformin. Overall glycemic efficacy and safety findings were similar compared to other trials discussed. Reductions in HbA1c were slightly lower than reductions seen in Phase III trials. This study lasted 18 weeks, and approximately 25% of patients at baseline had an HbA1c <7% which could account for the slightly lower HbA1c reduction of –0.44% and –0.60% in the 50 mg and 150 mg group, respectively.22
Safety and tolerability

Data were pooled from four 26-week placebo-controlled trials, one in which canagliflozin was used as monotherapy and three in which canagliflozin was used as an add-on therapy with metformin (with or without additional agents). During these trials, 1,667 patients were exposed to canagliflozin, and 1,275 patients were exposed to a combination of canagliflozin and metformin. The most commonly reported adverse events (>2%) for patients treated with canagliflozin were genital mycotic infections, urinary tract infections, increased urination, vulvovaginal pruritus, thirst, constipation, and nausea. Using data pooled from eight placebo- and active-controlled trials of 6,177 patients exposed to canagliflozin, in addition to the side effects listed above, fatigue and hypersensitivity reactions were also reported in >2% of patients.\(^1\)

Volume depletion-related adverse events, including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration, occurred more commonly in patients on the 300 mg dosage of canagliflozin and those on concomitant loop diuretics, those with moderate renal impairment (eGFR 30 mL/min/1.73 m\(^2\)) to less than 60 mL/min/1.73 m\(^2\), or those aged 75 years and older. Caution should also be used in patients taking medications that interfere with the renin–angiotensin–aldosterone system or those with a low SBP.\(^1\)

Data pooled from four placebo-controlled trials and a moderate renal impairment trial demonstrated a dose-dependent increase in serum creatinine in patients treated with canagliflozin. The dose of canagliflozin should be limited to 50 mg twice daily in patients with moderate renal impairment (eGFR 45 mL/min/1.73 m\(^2\)) to less than 60 mL/min/1.73 m\(^2\)). Hypoglycemia is more likely to occur when canagliflozin is used in combination with sulfonylureas or insulin therapy; therefore, a lower dose of these agents may be required. Dose-related increases in serum magnesium, serum potassium, LDL-cholesterol, and non-HDL-cholesterol have also occurred in placebo-controlled trials with canagliflozin. These laboratory parameters should be monitored.\(^1\)

The most common adverse events associated with metformin include diarrhea, nausea, vomiting, flatulence, asthenia, abdominal discomfort, and headache. The dose should be gradually escalated to decrease the risk of gastrointestinal side effects. In the long term, metformin has been associated with vitamin B\(_{12}\) deficiency, and its levels should be monitored annually.\(^1\)

Lactic acidosis can occur in the event of metformin accumulation. Patients with renal impairment, sepsis, dehydration, excess alcohol intake, hepatic impairment, and acute congestive heart failure have an increased risk. Metformin should not be used when the serum creatinine level is greater than or equal to 114.4 \(\mu\)mol/L in men or 106.8 \(\mu\)mol/L in women. Metformin should be temporarily discontinued at the time of or prior to radiologic studies and held for at least 48 hours and until renal function is determined to be normal. It should also be held for surgical procedures requiring food and fluid restrictions until oral intake is resumed and renal function is found to be normal.\(^1\)

Patient-focused perspectives

Patients’ acceptance of a treatment regimen is an important factor to consider when choosing the most appropriate therapy. The patient must buy-in to the regimen in order for it to be effective. Even the best treatment will not work if the patient is not willing to take it, stops taking it, or does not take it as instructed. One study administered a validated questionnaire to patients with type 2 diabetes in an outpatient clinic in Jordan. This included a self-reported medication adherence scale (Morisky Scale), diabetes knowledge questionnaire (ADKnowl Questionnaire), and health-related quality of life (HRQoL) scale (EQ-5D Questionnaire). Patients were about nine times less likely to adhere to diabetes medications if they received more than one dose of medication per day, and the odds of adherence was inversely related to the number of medications prescribed; therefore, simplifying regimens, like using an FDC, can be beneficial.\(^2\)

Side effects are a major factor that can affect adherence.\(^2\) While side effects are not benign, as discussed previously, the canagliflozin metformin combination was generally well tolerated in the Phase III study of canagliflozin vs placebo and sitagliptin in patients on background metformin with slightly less serious adverse events reported in the canagliflozin groups (100 mg and 300 mg) compared to the combination with sitagliptin (4.1%, 3.3%, and 4.9%, respectively).\(^3\) There are also several side effects that may be advantageous for patients. Weight loss, reduced blood pressure, and increased HDL-cholesterol are associated with the canagliflozin and metformin combination.\(^2\) With the numerous diabetes medications that are associated with weight gain, patients already struggling with obesity may find this discouraging as it can make it more difficult for them to meet their weight loss goals. The combination of a weight neutral medication, metformin, and a medication that has the potential for weight loss, canagliflozin, may appeal to these patients specifically.\(^4\)

Hypoglycemia, another side effect of many diabetes medications, has the potential to affect many aspects of patients’
lives such as quality of life, work productivity, and medication adherence. One study assessed hypoglycemia as related to the patient’s perspective. Out of 6,065 patients treated with oral or injectable agents for diabetes, 56% of participants self-reported hypoglycemia, and of those, 29% experienced hypoglycemia recently. Of the patients who reported recent hypoglycemia, 60.9% had a low or medium adherence score, while only 39.1% had a high adherence score (based on Morisky Scale). More patients on diabetes medications with recent hypoglycemia reported interference with social activities in the previous 4 weeks compared to patients who never had hypoglycemia. A greater percentage of patients were absent from work in the recent hypoglycemia group compared to the group who never had hypoglycemia (7.6% vs 3.5%, $P<0.001$). Also, 25.5% of patients with recent hypoglycemia indicated work productivity impairment, while only 16.3% reported this in the group that never had hypoglycemia ($P<0.001$). The Short Form-36 health survey, version 2, and questions from the US National Health and Wellness Survey were used to assess HRQoL. Overall HRQoL decreased in those who had experienced recent or any past hypoglycemia more so than the group who never reported hypoglycemia.\(^\text{24}\)

Given the low incidence of hypoglycemia associated with metformin and canagliflozin in clinical trials, one could extrapolate that this may in turn lead to improved adherence to medications, less interference with social activities, less missed work days, and an overall improvement in HRQoL.\(^\text{24,25}\)

As highlighted above, the combination of canagliflozin and metformin has many qualities that may be promising from the patient’s perspective.

Canagliflozin–metformin is available in the following strengths: canagliflozin 50 mg/metformin 500 mg, canagliflozin 50 mg/metformin 1,000 mg, canagliflozin 100 mg/metformin 500 mg, and canagliflozin 100 mg/metformin 1,000 mg. The maximum recommended dose for combination is canagliflozin 300 mg and metformin 2,000 mg per day in divided doses. In patients with an eGFR of at least 45–60 mL/min/1.73 m\(^2\), the total dose of canagliflozin should not exceed 100 mg per day in divided doses. Patients should be counseled on taking this medication twice daily with food to decrease the incidence of gastrointestinal side effects seen with metformin.\(^\text{13}\)

**Place in therapy**

According to the American Diabetes Association (ADA), the initial approach to therapy should be based on patient-specific factors and the baseline HbA\(_{1c}\). In addition to lifestyle modifications, metformin monotherapy is considered to be the appropriate initial medication for most patients who are newly diagnosed with T2DM. The ADA goes on to suggest initiating combination therapy in patients who have an HbA\(_{1c}\) of at least 9% with a preference toward combination therapy with insulin in patients with an HbA\(_{1c}\) greater than 10%.\(^\text{21}\) The American Association of Clinical Endocrinologists (AACE) takes a more aggressive approach to management of T2DM and suggests initiating combination therapy in patients with an HbA\(_{1c}\) higher than 7.5% and suggests adding insulin to that combination in patients with an HbA\(_{1c}\) greater than 9%.\(^\text{26}\)

Given these respected recommendations from ADA and AACE, one must ask where the combination of metformin and canagliflozin should be considered. In an otherwise healthy population, this combination could be considered as an initial therapy in patients with an HbA\(_{1c}\) of at least 7.5% if an aggressive approach is the target. In populations where a less aggressive approach is the target (elderly, multiple comorbid disease states, limited life expectancy, etc), this combination could be considered as an initial treatment option in patients with an HbA\(_{1c}\) of at least 9%. Patients on metformin monotherapy who have not reached their goal within 3 months could also be considered for the canagliflozin–metformin combination. At this point, use of canagliflozin–metformin with insulin therapy has not yet been evaluated in clinical trials, and use of this combination should be done with caution.

Given the availability of other combinations with metformin, one must also consider when to use canagliflozin–metformin or one of the other combination agents. One of the key benefits seen in patients treated with canagliflozin that presents a clinical edge is the potential for weight reduction. With most diabetes agents either causing weight gain or being weight neutral, this is one of the few add-ons that could result in a modest weight reduction. Combination canagliflozin–metformin could also present an advantage in patients who have hypertension given its ability to reduce SBP. Use of this agent should be cautioned in patients who have had a significant history of genital mycotic infections, hypotension, or poor renal function.

Overall, the combination of canagliflozin–metformin appears to be a safe and effective option for patients with T2DM with a moderately elevated HbA\(_{1c}\) (7.5%–10%). The potential for reduction in weight and SBP gives this combination an advantage over combinations containing a sulfonylurea or DPP-4 inhibitor, but this must be weighed out with the potential complication of genital mycotic infections and hypotension. Treatment of T2DM continues to evolve,
and combinations such as canagliflozin–metformin represent a promising option for patients struggling to obtain control of their gluoses.

**Disclosure**

No relevant financial disclosures or conflicts of interest to report for any of the above-listed authors.

**References**


